Fusion Antibodies
A CRO that offers a range of world class services in antibody production, development, characterization and optimization.
Launch date
Employees
Market cap
CAD5.8m
Enterprise valuation
CAD4m (Public information from Sep 2024)
Share price
£0.03243 FAB.L
Company register number NI039740
Lisburn Northern Ireland (HQ)
Financials
Estimates*
| GBP | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 3.9m | 4.2m | 4.8m | 2.9m | 1.1m |
| % growth | - | - | - | 7 % | 15 % | (40 %) | (61 %) |
| EBITDA | (<1m) | (1.1m) | (<1m) | (<1m) | (<1m) | (2.5m) | (1.6m) |
| % EBITDA margin | - | - | (11 %) | (13 %) | (12 %) | (86 %) | (142 %) |
| Profit | - | - | (<1m) | (2.9m) | (1.2m) | (2.6m) | (1.7m) |
| % profit margin | - | - | (18 %) | (70 %) | (25 %) | (89 %) | (152 %) |
| EV / revenue | - | - | 5.1x | 9.7x | 3.3x | 3.5x | 2.6x |
| EV / EBITDA | - | -5.8x | -46.0x | -75.6x | -27.2x | -4.0x | -1.8x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$2.5m | Early VC | ||
€270k | Grant | ||
N/A | Grant | ||
| N/A | €7.5m Valuation: €20.5m 342.9x EV/LTM EBITDA | IPO | |
N/A | Grant | ||
* | N/A | £1.4m | Post IPO Equity |
| Total Funding | CAD3.8m | ||
Related Content
Recent News about Fusion Antibodies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.